



Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Date Published: Thursday, 12 Sep 2024

DETAILED NEWS

SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024. MASH Drug Development Summit Presentation Details: Presentation Title:

- Demonstrating denifanstat's differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity Presenter: Marie O'Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet Biosciences Session: Showcasing Antifibrotic Progress, Past Learnings & Innovations to Supercharge MASH Drug Development Date and time: Thursday, September 26, 2024, 4:15 – 4:45pm ET About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.

- Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH.

- FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results.

- For additional information about Sagimet, please visit www.sagimet.com. About MASH MASH is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe.

- In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH.

- Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver.

- The goal of the name change was to establish an affirmative, non-stigmatizing name and diagnosis. Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.

↪ All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet's clinical development plans and related anticipated development milestones, Sagimet's cash and financial resources and expected cash runway.

↪ These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

↪ In some cases, these statements can be identified by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

↪ Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations.

↪ These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet's control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet's ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet's relationship with Ascleptis, and the success of its development efforts for denifanstat; the accuracy of Sagimet's estimates regarding its capital requirements; and Sagimet's ability to maintain and successfully enforce adequate intellectual property protection.

↪ These and other risks and uncertainties are described more fully in the "Risk Factors" section of Sagimet's most recent filings with the Securities and Exchange Commission and available at www.sec.gov.

↪ You should not rely on these forward-looking statements as predictions of future events.

↪ The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.

↪ Moreover, Sagimet operates in a dynamic industry and economy.

↪ New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face.

↪ Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Joyce Allaire LifeSci Advisors Jallaire@lifesciadvisors.com Source: Sagimet Biosciences Inc.

KEY HIGHLIGHTS

- ↳ - Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, has announced an oral presentation on their drug denifanstat at the 8th Annual MASH Drug Development Summit in Boston from September 24-26, 2024.
- ↳ The presentation will highlight the drug's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH).
- ↳ - The presentation, titled "Demonstrating denifanstat's differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity," will be given by Marie O'Farrell, Senior Vice President of Research and Development at Sagimet Biosciences.
- ↳ - Sagimet is focused on developing fatty acid synthase (FASN) inhibitors to target dysfunctional metabolic pathways in diseases that result from the overproduction of the fatty acid, palmitate.
- ↳ Their lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor being developed for the treatment of MASH.
- ↳ - The drug recently completed a Phase 2b clinical trial (FASCINATE-2) with positive results.
- ↳ More than 115 million people worldwide are estimated to be affected by MASH, a severe liver disease for which there is only one recently approved treatment in the United States and none in Europe.
- ↳ - In 2023, global liver disease medical societies and patient groups decided to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH.
- ↳ An overarching term, steatotic liver disease (SLD), was also established to encompass multiple types of liver diseases associated with fat buildup in the liver.